Precision BioSciences to Present at Guggenheim Healthcare Talks 2021 Oncology Day
DURHAM, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS® genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on February 11, 2021 at 2:00 PM ET.
A live webcast of the presentation will be accessible on the Company’s website, , in the Investors & Media section under Events and Presentations. An archived replay of the webcasts will be available for approximately 30 days following the presentation.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit .
Investor Contact:
Alex Kelly
Interim Chief Financial Officer
Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
